Company Description
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies.
The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells.
In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers.
The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023.
The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | James Bianco |
Contact Details
Address: 10500 University Center Drive, Suite 110 Tampa, Florida 33612 United States | |
| Phone | 813 875 6600 |
| Website | tuhurabio.com |
Stock Details
| Ticker Symbol | HURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001498382 |
| ISIN Number | US8989201038 |
| Employer ID | 99-0360497 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James A. Bianco M.D. | President, Chief Executive Officer and Director |
| Dan Dearborn CPA | Executive Vice President of Finance and Chief Financial Officer |
| Michael Lawman | Co-Founder |
| Patricia Lawman | Co-Founder |
| Michael Krsulich | Head of Quality Assurance |
| Dr. Bertrand Le Bourdonnec Ph.D. | Executive Vice President, Head of Drug Discovery, Early Development, and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 12, 2025 | 8-K/A | [Amend] Current report |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 8-K | Current Report |
| Jun 13, 2025 | D | Notice of Exempt Offering of Securities |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 6, 2025 | 8-K | Current Report |
| May 23, 2025 | ARS | Filing |